Patents Assigned to Amgen Inc.
  • Publication number: 20240200115
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Application
    Filed: February 27, 2024
    Publication date: June 20, 2024
    Applicant: Amgen Inc.
    Inventors: Chung-Jr HUANG, SR., Xiaoming YANG
  • Publication number: 20240197922
    Abstract: Methods of manufacturing a biological therapy are described. The methods can comprise detecting a level of a molecular attribute of the biological therapy in a formulation, determining a rate of change of the molecular attribute under the storage conditions, and estimating a level of molecular attribute exposure received by the subjects at the time of said administration. Production lots of the biological therapy comprising the molecular attribute can be manufactured comprising the molecular attribute at or below a specified specification for permissible levels of the molecular attribute based on the estimated level of molecule attribute exposure. Methods of developing a manufacturing process for a biological therapy are described. Methods of assessing the clinical impact of a molecular attribute of a biological therapy are described.
    Type: Application
    Filed: June 13, 2023
    Publication date: June 20, 2024
    Applicant: AMGEN INC.
    Inventors: Nathan JOH, Marisa JOUBERT, Gerd Richard KLEEMAN, Linda Owers NARHI, Noel J. RIEDER, Joshua TOKUDA, Zhongqi ZHANG, Yunlong ZHANG
  • Patent number: 12012462
    Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: June 18, 2024
    Assignee: Amgen Inc.
    Inventors: Michael John Giffin, Melissa Thomas, Christopher Murawsky, Ryan B. Case, Lawren Wu, Jed J. Wiltzius, Ruben Alvarez Rodriguez, Jun Feng
  • Patent number: 12012449
    Abstract: Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: June 18, 2024
    Assignee: AMGEN INC.
    Inventors: Jennifer E. Towne, Janet D. Cheng, Jason C. O'Neill, Yu Zhang, Yu Sun, Heather Cerne, Derek E. Piper, Randal R. Ketchem
  • Publication number: 20240182600
    Abstract: The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges particularly in regard to achieving acceptable expression levels free from mis-paired polypeptides. The presently claimed invention is directed to multispecific antigen binding proteins which improve upon existing charge pair technologies by redistributing the engineered charges within the CH3 regions of a heteromultimer.
    Type: Application
    Filed: April 19, 2022
    Publication date: June 6, 2024
    Applicant: AMGEN INC.
    Inventors: Danyang GONG, Bram ESTES, Zhulun WANG, Fernando GARCES
  • Patent number: 12000915
    Abstract: Disclosed herein is a method of conducting direct detection 1H solid state NMR (“ssNMR”) on a macromolecule-containing solid state formulation. The method includes conducting a 1H spin-lattice relaxation time (“T1”) experiment on the solid state formulation at various temperatures to generate a T1 value at each temperature, converting the T1 values to 1H spin-lattice relaxation rate (“R1”), and plotting R1 versus temperature to generate a relaxation rate curve for the solid state formulation. The relaxation rate curve can be analyzed to determine the molecular mobility of the macromolecule in the solid state formulation, the degree of aggregation in the solid state formulation, and/or the stability of the solid state formulation.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: June 4, 2024
    Assignee: AMGEN INC.
    Inventors: Marc A. Caporini, Ron C. Kelly, Mariana De Maillé
  • Patent number: 12000775
    Abstract: Disclosed are methods of determining the suitability of a variable-length spectrophotometer using Patent Blue dye or AMG Blue dye. Also disclosed herein are methods of determining the suitability of a fixed path length spectrophotometer for determining protein concentration of a protein sample. AMG Blue dye may also be used to determine the suitability of fixed path length spectrophotometers.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: June 4, 2024
    Assignee: Amgen Inc.
    Inventors: Robert John Duff, Christian Gutierrez
  • Publication number: 20240174752
    Abstract: The present invention relates to the field of biopharmaceutical manufacturing. In particular, the invention relates to using temperature as a lever to modulate product quality during upstream operations.
    Type: Application
    Filed: April 26, 2022
    Publication date: May 30, 2024
    Applicant: AMGEN INC.
    Inventors: Li ZHANG, Hedieh BARKHORDARIAN, Ewelina ZASADZINSKA, Jonathan DIEP
  • Publication number: 20240173328
    Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 30, 2024
    Applicant: Amgen Inc.
    Inventors: James Russell LIPFORD, Jude Robert CANON, Anne Y. SAIKI, Karen Louise REX
  • Patent number: 11993663
    Abstract: The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: May 28, 2024
    Assignee: AMGEN INC.
    Inventors: Joon Hoi Huh, Riki Stevenson, Pavel Bondarenko, Andrew Nichols, Da Ren, Neeraj Jagdish Agrawal, Richard Smith
  • Patent number: 11993597
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: May 28, 2024
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee
  • Patent number: 11992659
    Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: May 28, 2024
    Assignee: AMGEN INC.
    Inventors: Adam B. McCullough, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler, Basel Hasan Taha, Jimmie L. Ward, Christopher R. Folk, Steven William Badelt
  • Publication number: 20240165338
    Abstract: A drug delivery device may include a housing defining a longitudinal axis and having an opening and a drug storage container including a barrel, a stopper and a delivery member, the stopper movably positioned within the barrel and the delivery member positioned at a distal end of the barrel and having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include plunger moveable toward the distal end of the drug storage container to engage the stopper and expel a drug from the drug storage container through the delivery member, the plunger including a body portion and a shock absorbing portion. The device may further include a plunger biasing member coupled with the plunger and configured to urge the plunger toward the distal end of the drug storage container.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 23, 2024
    Applicant: AMGEN INC.
    Inventors: Jan Mikael JENSEN, Lars EILERTSEN
  • Patent number: 11986624
    Abstract: An insertion mechanism for a drug delivery device including a trocar, a housing, and a manifold in fluid communication with a fluid pathway connector and movable relative to the housing between a first manifold position adjacent to a proximal end of the housing and a second manifold position adjacent to a distal end of the housing. A hub carrying the trocar or hollow delivery needle is removably connected to the manifold, the hub being movable relative to the housing between a first hub position adjacent to the proximal end of the housing and a second hub position adjacent to the distal end of the housing. A power source is configured to generate rotational motion. A motion conversion mechanism operatively connects the power source and the hub, and is configured to convert the rotational motion into linear motion of the hub.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: May 21, 2024
    Assignee: AMGEN INC.
    Inventors: Adam B. McCullough, Erich Coiner, Alan D. Payne
  • Patent number: 11986643
    Abstract: An autoinjector apparatus is disclosed which comprises a single-use cassette and an autoinjector. The cassette comprises a housing and a sleeve movably disposed in the housing. A syringe may be disposed in the sleeve and secured therein with a lock cap. The lock cap is affixed to a distal end of the sleeve and contacts the distal end of the syringe. A shield remover extends through an opening in a proximal end of the housing for removing a needle shield which covers a needle of the syringe. A cassette identification arrangement is provided on a surface of the housing to enable the autoinjector to identify the cassette. The autoinjector is provided with a detector for reading the cassette identification arrangement.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: May 21, 2024
    Assignee: AMGEN INC.
    Inventors: Michael Denzer, Robert W. Swift, Neal Johnston, Gabriele Ganzitti, Kenneth R. Ewing, Suhas Krishna
  • Publication number: 20240157057
    Abstract: A real-time drug injection time duration measurement system includes a sound transducer, a waveform shaping circuit operably coupled therewith, a pulse clamping circuit operably coupled with the waveform shaping circuit, and a timer operably coupled with the pulse clamping circuit. The sound transducer detects a first sound associated with drug delivery initiation and a second sound associated with drug delivery completion and is further converts the detected first and second sounds into a first electronic waveform and a second electronic waveform, respectively. The waveform shaping circuit converts the first and second waveforms into a first pulse and a second pulse, respectively. The pulse clamping circuit triggers upon receiving the first pulse and generate a regenerated pulse. The timer initiates upon receiving the regenerated pulse and stop upon receiving a subsequent regenerated pulse via the pulse clamping circuit.
    Type: Application
    Filed: March 28, 2022
    Publication date: May 16, 2024
    Applicant: AMGEN INC.
    Inventors: Huixing Jin, Julian JAZAYERI, Sergio Giovanni VALENZUELA, Ryan David SELVE, Sivakumar PARAMANANDAM
  • Publication number: 20240150448
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 9, 2024
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Patent number: 11976103
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: May 7, 2024
    Assignee: Amgen Inc.
    Inventors: Eric Alan Butz, Christy Ann Thomson, Marc Alain Gavin, Ian Nevin Foltz, Dong Xia, Dina N. Alcorn, Randal Robert Ketchem, Ai Ching Lim, Kathy Manchulenko, Laura Sekirov, Kelly Ann Berry, Cyr Clovis Chua De Imus, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Li Li
  • Patent number: D1030040
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: June 4, 2024
    Assignee: AMGEN INC.
    Inventors: Peter Dan Kaare Soelberg, Kasper Poder, Rasmus Ohlenschlager, Dylan Bourelle
  • Patent number: D1030041
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: June 4, 2024
    Assignee: AMGEN INC.
    Inventors: Peter Dan Kaare Soelberg, Kasper Poder, Rasmus Ohlenschlager, Dylan Bourelle